Efficacy and Safety of NYT in Treatment-Resistant Schizophrenia: Open-Label Study

Efficacy and Safety of NYT in Treatment-Resistant Schizophrenia: Open-Label Study - NYT for Treatment-Resistant Schizophrenia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028462

Enrollment

Registered

2017-07-31

Start date

2016-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Schizophrenia patients, 20-59 age.

Exclusion criteria

Exclusion criteria: Exclusion criteria included pregnancy, lactation, other clinical significant or unstable conditions, and history of alcohol or substance abuse in the last 6 months. No patients had been treated by clozapine in this clinical trial.

Design outcomes

Primary

Measure	Time frame
During a 12-week follow-up, psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS)	—

Countries

Japan

Contacts

Public ContactTsuyoshi Miyaoka

Shimane University Psychiatry

miyanyan@med.shimane-u.ac.jp853-20-2262

Outcome results